Exelixis Competitors

Amgen (NASDAQ:AMGN) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Volatility & Risk

Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500.

Earnings & Valuation

This table compares Amgen and Exelixis' revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Exelixis. Amgen is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 81.4% of Exelixis shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 4.5% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Amgen and Exelixis' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Amgen and Exelixis, as provided by MarketBeat.

Amgen currently has a consensus price target of $255.6190, indicating a potential upside of 1.69%. Exelixis has a consensus price target of $33.00, indicating a potential upside of 29.11%. Given Exelixis' stronger consensus rating and higher possible upside, analysts clearly believe Exelixis is more favorable than Amgen.

Gilead Sciences (NASDAQ:GILD) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Risk & Volatility

Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Earnings and Valuation

This table compares Gilead Sciences and Exelixis' gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Exelixis. Gilead Sciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 81.4% of Exelixis shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 4.5% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Exelixis' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Gilead Sciences and Exelixis, as provided by MarketBeat.com.

Gilead Sciences currently has a consensus price target of $100.5909, indicating a potential upside of 46.78%. Exelixis has a consensus price target of $33.00, indicating a potential upside of 29.11%. Given Gilead Sciences' higher probable upside, equities analysts plainly believe Gilead Sciences is more favorable than Exelixis.

Summary

Gilead Sciences beats Exelixis on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Exelixis' gross revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 81.4% of Exelixis shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 4.5% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Vertex Pharmaceuticals and Exelixis' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Vertex Pharmaceuticals and Exelixis, as provided by MarketBeat.com.

Vertex Pharmaceuticals currently has a consensus price target of $293.4737, indicating a potential upside of 35.19%. Exelixis has a consensus price target of $33.00, indicating a potential upside of 29.11%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Vertex Pharmaceuticals is more favorable than Exelixis.

Summary

Vertex Pharmaceuticals beats Exelixis on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Risk & Volatility

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Exelixis' gross revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Exelixis. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 81.4% of Exelixis shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 4.5% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Regeneron Pharmaceuticals and Exelixis' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Regeneron Pharmaceuticals and Exelixis, as provided by MarketBeat.com.

Regeneron Pharmaceuticals currently has a consensus price target of $656.3810, indicating a potential upside of 27.05%. Exelixis has a consensus price target of $33.00, indicating a potential upside of 29.11%. Given Exelixis' stronger consensus rating and higher probable upside, analysts plainly believe Exelixis is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Exelixis on 9 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Risk & Volatility

Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Biogen and Exelixis, as provided by MarketBeat.com.

Biogen currently has a consensus price target of $305.5714, indicating a potential upside of 9.05%. Exelixis has a consensus price target of $33.00, indicating a potential upside of 29.11%. Given Exelixis' stronger consensus rating and higher probable upside, analysts plainly believe Exelixis is more favorable than Biogen.

Earnings and Valuation

This table compares Biogen and Exelixis' gross revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Exelixis. Biogen is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biogen and Exelixis' net margins, return on equity and return on assets.

Institutional and Insider Ownership

83.5% of Biogen shares are held by institutional investors. Comparatively, 81.4% of Exelixis shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Comparatively, 4.5% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Biogen beats Exelixis on 8 of the 14 factors compared between the two stocks.

Exelixis (NASDAQ:EXEL) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Volatility & Risk

Exelixis has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Exelixis and Alexion Pharmaceuticals, as provided by MarketBeat.

Exelixis presently has a consensus price target of $33.00, indicating a potential upside of 29.11%. Alexion Pharmaceuticals has a consensus price target of $159.3158, indicating a potential downside of 8.17%. Given Exelixis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Exelixis is more favorable than Alexion Pharmaceuticals.

Valuation and Earnings

This table compares Exelixis and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Exelixis. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Exelixis and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

81.4% of Exelixis shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.5% of Exelixis shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Alexion Pharmaceuticals beats Exelixis on 8 of the 14 factors compared between the two stocks.